Metozolv ODT approved for diabetic gastroparesis and symptomatic documented gastroesophageal reflux disease (GERD)

The FDA has approved Metozolv ODT (metoclopramide HCl orally disintegrating tablets, from Salix) for short-term therapy (4–12 weeks) in adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults.

Metozolv ODT is expected to be made available November 2009 in 5mg and 10mg dosage strengths.

For more information call (800) 508-0024 or visit www.salix.com.